LC
DAWN

Lindbrook Capital’s Day One Biopharmaceuticals DAWN Stock Holding History

Lindbrook Capital’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$1.13K Buy
+142
New +$1.53K ﹤0.01% 2430

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
ECM
Estuary Capital Management Wayzata, Minnesota $598M AUM 1.72% 1-Year Est. Return

Lindbrook Capital's DAWN Position: Q1 2025 in Review

Lindbrook Capital opened a new position in Day One Biopharmaceuticals (DAWN) in Q1 2025: 142 shares worth $1.13K. The stake represents ﹤0.01% of the portfolio and ranks #2430 among its holdings.

184 funds tracked by Wall St. Rank hold DAWN as of Q1 2025.

  • Lindbrook Capital held 142 shares of Day One Biopharmaceuticals worth $1.13K as of Q1 2025.
  • Day One Biopharmaceuticals was a new Lindbrook Capital position in Q1 2025.
  • Day One Biopharmaceuticals made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2430 holding.
  • 184 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.